Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2017 | May 10, 2017 | |
Document And Entity Information | ||
Entity Registrant Name | Boston Therapeutics, Inc. | |
Entity Central Index Key | 1,473,579 | |
Document Type | 10-Q | |
Trading Symbol | BTHE | |
Document Period End Date | Mar. 31, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity a Well-known Seasoned Issuer | No | |
Entity a Voluntary Filer | No | |
Entity's Reporting Status Current | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 47,741,137 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2,017 |
Condensed Balance Sheets (Unaud
Condensed Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2017 | Dec. 31, 2016 |
Current assets: | ||
Cash and cash equivalents | $ 389,924 | $ 687,185 |
Accounts receivable | 591 | 5,011 |
Prepaid expenses and other current assets | 92,332 | 82,710 |
Inventory, net | 54,557 | 55,116 |
Total current assets | 537,404 | 830,022 |
Property and equipment, net | 3,836 | 1,577 |
Intangible assets, net | 487,500 | 503,571 |
Goodwill | 69,782 | 69,782 |
Total assets | 1,098,522 | 1,404,952 |
Current liabilities: | ||
Accounts payable | 349,677 | 319,474 |
Accrued expenses and other current liabilities | 353,172 | 347,405 |
Deferred revenue | 112,162 | 112,162 |
Notes payable - related party, current portion | 297,820 | 297,820 |
Total current liabilities | 1,112,831 | 1,076,861 |
Convertible notes payable, related party, net of discount | 909,126 | 754,461 |
Convertible notes payable, net of discount | 593,295 | 364,619 |
Warrant liability | 1,103,811 | 1,093,765 |
Derivative liability | 1,193,980 | 1,234,106 |
Total liabilities | 4,913,043 | 4,523,812 |
COMMITMENTS AND CONTINGENCIES | ||
Stockholders' deficit: | ||
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding | ||
Common stock, $0.001 par value, 400,000,000 shares authorized, 46,702,836 shares issued and outstanding at March 31, 2017 and December 31, 2016. | 46,703 | 46,703 |
Additional paid-in capital | 15,073,055 | 15,060,616 |
Accumulated deficit | (18,934,279) | (18,226,179) |
Total stockholders' deficit | (3,814,521) | (3,118,860) |
Total liabilities and stockholders' deficit | $ 1,098,522 | $ 1,404,952 |
Condensed Balance Sheets (Unau3
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2017 | Dec. 31, 2016 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, authorized | 5,000,000 | 5,000,000 |
Preferred Stock, issued | ||
Preferred stock, outstanding | ||
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized | 400,000,000 | 400,000,000 |
Common stock, issued | 46,702,836 | 46,702,836 |
Common stock, outstanding | 46,702,836 | 46,702,836 |
Condensed Statements of Operati
Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Income Statement [Abstract] | ||
Revenue | $ 4,479 | $ 12,307 |
Cost of goods sold | 8,933 | 15,922 |
Gross (deficit) margin | (4,454) | (3,615) |
Operating expenses: | ||
Research and development | 41,707 | 21,772 |
Sales and marketing | 13,513 | 18,650 |
General and administrative | 235,647 | 213,957 |
Total operating expenses | 290,867 | 254,379 |
Operating loss | (295,321) | (257,994) |
Other income (expenses): | ||
Interest expense | (442,859) | (157,341) |
Other expense | (4,010) | |
Change in fair value of warrant liability | (10,046) | |
Change in fair value of derivative liabilities | 40,126 | |
Net loss | $ (708,100) | $ (419,345) |
Net loss per share- basic and diluted (in dollars per share) | $ (0.02) | $ (0.01) |
Weighted average shares outstanding basic and diluted (in shares) | 46,702,836 | 39,319,507 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Cash flows from operating activities: | ||
Net loss | $ (708,100) | $ (419,345) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 17,126 | 17,716 |
Stock-based compensation | 12,439 | |
Amortization of discount on debt and deferred financing costs | 383,341 | 117,654 |
Change in fair value of warrant liability | 10,046 | |
Change in fair value of derivative liabilities | (40,126) | |
Changes in operating assets and liabilities: | ||
Accounts receivable | 4,420 | (2,595) |
Inventory | 559 | 5,782 |
Prepaid expenses and other current assets | (9,622) | 223 |
Other assets | 3,625 | |
Accounts payable | 30,203 | (21,147) |
Accrued expenses | 5,767 | (104,277) |
Net cash used in operating activities | (293,947) | (402,364) |
Cash flows from investing activities: | ||
Purchase of equipment | (3,314) | |
Net cash used in investing activities | (3,314) | |
Cash flows from financing activities: | ||
Proceeds from issuance of convertible notes payable (net of issuance discounts and fees) | 402,000 | |
Net cash provided by financing activities | 402,000 | |
Net (decrease) in cash and cash equivalents | (297,261) | (364) |
Cash and cash equivalents, beginning of period | 687,185 | 40,995 |
Cash and cash equivalents, end of period | 389,924 | 40,631 |
Cash paid during the period for: | ||
Interest | 7,136 | |
Income taxes | 4,000 | |
Non-cash financing activities: | ||
Beneficial conversion features associated with convertible notes payable | $ 402,000 |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES | 3 Months Ended |
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES | 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Company Overview Boston Therapeutics, Inc., headquartered in Lawrence, MA, (OTC: BTHE) is a leader in the field of complex carbohydrate chemistry. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: BTI-320, a non-systemic, non-toxic, therapeutic compound designed to reduce post-meal glucose elevation. In addition, a formulation of the material SUGARDOWN®, falls within the regulatory dietary supplement guidelines and is designed to reduce post-meal blood sugar increases. In its patent portfolio, the Company had laboratory practical development of a combination material called IPOXYN. In its initial phase, IPOXYN is a continuous intravenous drug for the prevention of necrosis and treatment of ischemia with a first target indication for assisting in the treatment of lower limb ischemia often associated with diabetes. The accompanying unaudited condensed financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and primarily a CRO/CMO contracted operating history. As shown in the accompanying unaudited condensed financial statements, the Company has an accumulated deficit of approximately $18.9 million and $390,000 cash on hand as of March 31, 2017. Management is restructuring and is currently seeking additional capital through private placements and public offerings of its common stock. In addition, the Company may seek to raise additional capital through public or private debt or equity financings as well as collaboration activities in order to fund our operations. Management anticipates that the current cash available will be sufficient to fund our planned operations into the second quarter of 2017. The future of the Company is dependent upon its ability to obtain continued financing and upon future profitable operations from the partnering, development and clarity of its new business opportunities. There can be no assurance that the Company will be successful in accomplishing its objectives. Without such additional capital, the Company may be required to cease operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue operations. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q. These condensed financial statements should be read in conjunction with the Company's financial statements for its year ended December 31, 2016 included in its Form 10-K filed with the SEC on March 28, 2017. In the opinion of management, the statements contain all adjustments, including normal recurring adjustments necessary in order to present fairly the financial position as of March 31, 2017 and the results of operations for the three month periods ended March 31, 2017 and 2016. The condensed balance sheet, as of December 31, 2016, was derived from the audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results disclosed in the statements of operations for the three month period ended March 31, 2017 are not necessarily indicative of the results to be expected for the full fiscal year. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Accounts Receivable Accounts receivable is stated at the amount management expects to collect from outstanding balances. Management establishes a reserve for doubtful accounts based on its assessment of the current status of individual accounts. Balances that remain outstanding after management has used reasonable collection efforts are written off against the allowance. There were no allowances for doubtful accounts as of March 31, 2017 and December 31, 2016. Inventory Inventory consists of raw materials, and finished goods of SUGARDOWN®. Inventories are stated at the lower of cost (first-in, first-out) or market, not in excess of net realizable value. The Company adjusts the carrying value of its inventory for excess and obsolete inventory. The Company continues to monitor the valuation of its inventory. Revenue Recognition The Company generates revenues from sales of SUGARDOWN®. Revenue is recognized when there is persuasive evidence that an arrangement exists, the price is fixed and determinable, the product is shipped in accordance with the customers’ Free On Board (FOB) shipping point terms and collectability is reasonably assured. In practice, the Company has not experienced or granted significant returns of product. Shipping fees charged to customers are included in revenue and shipping costs are included in costs of sales. Fair Value of Financial Instruments Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and notes payable. The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates fair value due to their short-term nature using level 3 inputs as defined above. The carrying value of the notes payable as of March 31, 2017 and December 31, 2016, evaluated using level 3 inputs defined above based on quoted market prices on rates available to the Company for debt with similar terms and maturities, approximates the fair value. Convertible Instruments U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable ASC 480-10. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company’s free standing derivatives consisted of warrants to purchase common stock that were issued in connection with the issuance of debt and of embedded conversion options with senior convertible debentures. The Company evaluated these derivatives to assess their proper classification in the balance sheet as of March 31, 2017 using the applicable classification criteria enumerated under ASC 815-Derivatives and Hedging. The Company determined that certain embedded conversion and/or exercise features do not contain fixed settlement provisions. The convertible debentures contain a conversion feature such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the debt and warrant derivatives which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period. Stock-Based Compensation Stock–based compensation, including grants of employee and non-employee stock options and modifications to existing stock options, is recognized in the income statement based on the estimated fair value of the awards . The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company has a limited history of market prices of the common stock, and as such volatility is estimated using historical volatilities over the prior three years. The expected life of the awards is estimated based on the simplified method. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of our awards. The dividend yield assumption is based on history and expectation of paying no dividends. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense is recognized in the financial statements on a straight-line basis over the vesting period, based on awards that are ultimately expected to vest. The Company grants stock options to non-employee consultants from time to time in exchange for services performed for the Company. Equity instruments granted to non-employees are subject to periodic revaluation over their vesting terms. In general, the options vest over the contractual period of the respective consulting arrangement and, therefore, the Company revalues the options periodically and records additional compensation expense related to these options over the remaining vesting period. Loss per Share Basic net loss per share is computed based on the net loss for the period divided by the weighted average actual shares outstanding during the period. Diluted net loss per share is computed based on the net loss for the period divided by the weighted average number of common shares and common equivalent shares outstanding during each period unless the effect of such common equivalent shares would be anti-dilutive. Common stock equivalents represent the dilutive effect of the assumed exercise of certain outstanding stock options using the treasury stock method. The weighted average number of common shares for the three month period ended March 31, 2017 did not include 60,227,273, and 12,094,000 and 28,404,669 for convertible notes payable and accrued interest, options and warrants, respectively, because of their anti-dilutive effect. The weighted average number of common shares for the three month period ended March 31, 2016 did not include 6,289,000 and 12,424,669 for options and warrants, respectively, because of their anti-dilutive effect. Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows. |
INVENTORIES
INVENTORIES | 3 Months Ended |
Mar. 31, 2017 | |
Inventory Disclosure [Abstract] | |
INVENTORY | 2. INVENTORIES Inventories consist of material, labor and manufacturing overhead and are recorded at the lower of cost, using the weighted average cost method, or net realizable value. The components of inventories at March 31, 2017 and December 31, 2016, net of inventory reserves, were as follows: 2017 2016 Raw materials $ 34,919 $ 34,919 Finished goods 19,638 20,197 $ 54,557 $ 55,116 The Company periodically reviews quantities of inventory on hand and compares these amounts to expected usage of each particular product or product line. The Company records, as a charge to cost of sales, any amounts required to reduce the carrying value to net realizable value. |
INTANGIBLE ASSETS
INTANGIBLE ASSETS | 3 Months Ended |
Mar. 31, 2017 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS | 3. INTANGIBLE ASSETS The SUGARDOWN® technology and patent applications are being amortized on a straight-line basis over their useful lives of 14 years. Goodwill is not amortized, but is evaluated annually for impairment. Intangible assets consist of the following at March 31, 2017 and December 31, 2016: 2017 2016 SUGARDOWN® technology and patent applications $ 900,000 $ 900,000 Less accumulated amortization (412,500 ) (396,429 ) Intangible assets, net $ 487,500 $ 503,571 Amortization expense was $16,071 and $16,071 for the three months ended March 31, 2017 and 2016, respectively. |
FAIR VALUE OF FINANCIAL INSTRUM
FAIR VALUE OF FINANCIAL INSTRUMENTS | 3 Months Ended |
Mar. 31, 2017 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
FAIR VALUE OF FINANCIAL INSTRUMENTS | 4. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 — inputs that are unobservable based on an entity’s own assumptions, as there is little, if any, related market activity (for example, cash flow modeling inputs based on assumptions) Financial liabilities as of March 31, 2017 measured at fair value on a recurring basis are summarized below: March 31, Quoted Prices Significant Significant Derivative liability $ 1,193,980 $ - $ - $ 1,193,980 Warrant liability 1,103,811 - - 1,103,811 Total $ 2,297,791 $ - $ - $ 2,297,791 Financial liabilities as of December 31, 2016 measured at fair value on a recurring basis are summarized below: December 31, Quoted Prices Significant Significant Derivative liability $ 1,234,106 $ - $ - $ 1,234,106 Warrant liability 1,093,765 - - 1,093,765 Total $ 2,327,871 $ - $ - $ 2,327,871 The Company determined that certain conversion/exercise option related to a convertible note and issued warrants did not have fixed settlement provisions and are deemed to be derivative financial instruments, since the conversion/exercise prices was subject to reset adjustment should the Company issue any option to acquire the Company’s common stock lower than the conversion /exercise price. Accordingly, the Company was required to record such conversion/exercise options as a liability and mark such derivative to fair value each reporting period. Such instrument was classified within Level 3 of the valuation hierarchy. The fair value of the conversion/exercise options were calculated using a binomial lattice formula with the following weighted average assumptions during the three months ended March 31, 2017: Conversion option: At March 31, Inception 2017 Common Stock Closing Price $ 0.0945 $ 0.071 Conversion Price per Share $ 0.075 $ 0.075 Conversion Shares 21,333,334 21,333,334 Call Option Value 0.0839 0.056 Dividend Yield 0.00 % 0.00 % Volatility 212.53 % 214.34 % Risk-free Interest Rate 0.725 % 1.03 % Term 2.0 years 1.38 years Exercise option: At March 31, Inception 2017 Common Stock Closing Price $ 0.0945 $ 0.071 Conversion Price per Share $ 0.100 $ 0.100 Conversion Shares 16,000,000 16,000,000 Call Option Value 0.0929 0.069 Dividend Yield 0.00 % 0.00 % Volatility 212.53 % 214.34 % Risk-free Interest Rate 1.15 % 1.93 % Term 5.0 years 4.38 years The risk-free interest rate is the United States Treasury rate on the measurement date having a term equal to the remaining contractual life of the instrument. The volatility is a measure of the amount by which the Company’s share price has fluctuated or is expected to fluctuate. The dividend yield is 0% as the Company has not made any dividend payment and has no plans to pay dividends in the foreseeable future. Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s Chief Financial Officer, who reports to the Chief Executive Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer. Level 3 financial liabilities consist of the derivative liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility or interest free rate, in isolation, can significantly increase or decrease the fair value of the derivative liabilities. Changes in the values of the derivative liabilities are recorded as a component of other income (expense) on the Company’s condensed statements of operations. The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis using significant unobservable input for the three months ended March 31, 2017: Debt Warrant Derivative Liability Balance, December 31, 2016 $ 1,234,106 $ 1,093,765 Aggregate amount of derivative instruments issued - - Change in fair value of derivative liabilities (40,126 ) 10,046 Balance, March 31, 2017 $ 1,193,980 $ 1,103,811 |
CONVERTIBLE NOTES PAYABLE
CONVERTIBLE NOTES PAYABLE | 3 Months Ended |
Mar. 31, 2017 | |
Debt Disclosure [Abstract] | |
CONVERTIBLE NOTES PAYABLE | 5. CONVERTIBLE NOTES PAYABLE In August and September 2016, the Company issued senior convertible debentures for an aggregate of $1,600,000 (the “Convertible Debentures”) in exchange for an aggregate net cash proceeds of $1,327,300, net of financing costs. The Convertible Debentures have a stated interest rate of 6% per annum payable quarterly beginning June 30, 2017 and are due two years from the date of issuance, the latest due September 15, 2018 and are convertible into shares of the Company’s common stock at the option of the holder at a conversion price of $0.075 with certain anti-dilutive (reset) provisions and are subject to forced conversion if either i) the volume weighted average common stock price for each of any 10 consecutive trading days equals or exceeds $0.50, or (ii) the Company’s elects to lists a class of securities on a national securities exchange. As long as the convertible notes remain outstanding, the Company is restricted from incurring any indebtedness or liens, except as permitted (as defined), amend its charter in any matter that materially effects rights of noteholders, repay or repurchase more than de minimis number of shares of common stock other than conversion or warrant shares, repay or repurchase all or any portion of any indebtedness or pay cash dividends. In connection with the issuance of the Convertible Debentures, the Company issued an aggregate of 16,000,000 warrants to purchase the Company’s common stock at $0.10 per share, expiring five years from the date of issuance, the latest being September 15, 2021. These warrants contain a cashless exercise and certain anti-dilutive (reset) provisions. The Company determined that certain conversion/exercise option related to a convertible note and issued warrants did not have fixed settlement provisions and are deemed to be derivative financial instruments due to price protection features present in the conversion/ exercise price that are not consistent with a fixed for fixed model. The accounting treatment of derivative financial instruments requires that the Company record the fair value of the derivative as of the issuance date of the debenture and warrants and to re-measure the derivatives at fair value as of each subsequent reporting date. The Company recognized the value attributable to the conversion feature of the convertible debenture and issued warrants of $2,203,336 and together with financing costs of $272,700 (aggregate of $2,476,036) as a discount against the notes up to $1,600,000 with the excess of $876,036 charged to interest during the three months ended September 30, 2016. The Company valued the conversion option and the warrants using the Binomial Lattice pricing model as described in Note 4. The debt discount is amortized over the note’s maturity period as interest expense. For the three months ended March 31, 2017, the Company amortized $197,260 debt discount to operations as interest expense. Convertible notes payable consist of the following at March 31, 2017 and December 31, 2016: 2017 2016 Principal balance $ 1,600,000 $ 1,600,000 Debt discount (833,923 ) (1,031,183 ) Deferred finance costs (172,782 ) (204,198 ) Outstanding, net of debt discount $ 593,295 $ 364,619 |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 3 Months Ended |
Mar. 31, 2017 | |
Equity [Abstract] | |
STOCKHOLDERS' EQUITY | 6. STOCKHOLDERS’ EQUITY The Company is authorized to issue up to 5,000,000 shares of its $0.001 par value preferred stock and up to 200,000,000 shares of its $0.001 par value common stock. During the year ended December 31, 2013, the Company amended its certificate of incorporation to increase the number of common shares from 100,000,000 to 200,000,000. The amendment went into effect on September 7, 2013. On November 2, 2015, the Company’s Board of Directors voted to approve an increase in authorized common stock shares outstanding from 200,000,000 shares to 400,000,000 shares of the Company’s common stock. This increase is subject to shareholder approval. Common Stock No shares of common stock were issued during the three months ended March 31, 2017 Common Stock Warrants The Company accounts for warrants as either equity instruments or liabilities depending on the specific terms of the warrant agreement. As of March 31, 2017, the Company had 28,404,669 warrants outstanding which are all classified as equity instruments and are fully exercisable as of March 31, 2017. The following table summarizes the Company’s common stock warrant activity during the three months ended March 31, 2017: Warrants Weighted Average Outstanding as of December 31, 2016 28,424,669 $ 0.29 Granted - - Exercised - - Forfeited/cancelled (20,000 ) 1.15 Outstanding as of March 31, 2017 28,404,669 $ 0.29 |
STOCK OPTION PLAN AND STOCK-BAS
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION | 3 Months Ended |
Mar. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION | 7. STOCK OPTION PLAN AND STOCK-BASED COMPENSATION During the year ended December 31, 2010, the Company adopted a stock option plan entitled “The 2010 Stock Plan” (“2010 Plan”) under which the Company may grant options to purchase up to 5,000,000 shares of common stock. On September 7, 2013, the 2010 plan was amended to increase the number of shares of common stock issuable under the 2010 Plan to 7,500,000. As of March 31, 2017 and December 31, 2016, there were 250,000 and 250,000 options outstanding under the 2010 Plan, respectively. During the year ended December 31, 2011, the Company adopted a non-qualified stock option plan entitled “2011 Non-Qualified Stock Plan” (“2011 Plan”) under which the Company may grant options to purchase 2,100,000 shares of common stock. In December 2012, the 2011 Plan was amended to increase the number of shares of common stock issuable under the 2011 Plan to 12,000,000 shares. During the period ended March 31, 2013, the 2011 Plan was amended to increase the number of shares of common stock issuable under the 2011 Plan to 17,500,000. As of March 31, 2017 and December 31, 2016, there were 11,844,000 and 12,039,000 options outstanding under the 2011 Plan, respectively. Under the terms of the stock plans, the Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options is typically one to four years and the options typically expire in five to ten years. No stock options were granted in either three month period ending March 31, 2017 or 2016. The Company recognized $12,439 and $0 of stock-based compensation costs in the accompanying statement of operations for the three months ended March 31, 2017 and 2016, respectively. As of March 31, 2017, there was $219,756 of unrecognized compensation expense related to non-vested stock option awards that is expected to be recognized in future periods. The following table summarizes the Company’s stock option activity during the three months ended March 31, 2017: Shares Exercise Price per Weighted Average Outstanding as of December 31, 2016 12,289,000 $ 0.10-1.21 $ 0.39 Granted - - - Exercised - - - Options forfeited/cancelled (195,000 ) 0.10 0.10 Outstanding as of March 31, 2017 12,094,000 $ 0.10-1.21 $ 0.39 There were no stock option exercises during the three months ended March 31, 2017 or March 31, 2016. The following table summarizes information about stock options that are vested or expected to vest at March 31, 2017: Vested or Expected to Vest Exercisable Options Weighted Weighted Weighted Weighted Average Average Average Average Exercise Remaining Aggregate Number Exercise Remaining Aggregate Exercise Number of Price Per Contractual Intrinsic of Price Contractual Intrinsic Price Options Share Life (Years) Value Options Per Share Life (Years) Value $ 0.10 1,600,000 $ 0.10 8.95 $ - 1,600,000 $ 0.10 8.95 $ - 0.18 934,000 0.18 6.25 - 934,000 0.18 6.25 - 0.20 2,150,000 0.20 4.66 - 2,150,000 0.20 4.66 - 0.37 58,000 0.37 5.42 - 58,000 0.37 5.42 - 0.40 2,000,000 0.40 4.42 - - 0.40 4.42 - 0.42 63,000 0.42 3.75 - 63,000 0.42 3.75 - 0.50 2,810,000 0.50 0.80 - 2,810,000 0.50 0.80 - 0.60 2,000,000 0.60 4.42 - - 0.60 4.42 - 0.69 100,000 0.69 7.00 - 100,000 0.69 7.00 - 1.21 379,000 1.21 6.78 - 379,000 1.21 6.78 - $ 0.10-1.21 12,094,000 $ 0.39 4.46 $ - 8,094,000 $ 0.39 4.46 $ - The weighted-average remaining contractual life for stock options exercisable at March 31, 2017 is 4.46 years. At March 31, 2017, the Company has 5,656,000 and 7,250,000 options available for grant under the 2011 Plan and 2010 Plan, respectively. There was $0 intrinsic value for fully vested, exercisable options at both March 31, 2017 and December 31, 2016. There were no options exercised in the three months ended March 31, 2017 or March 31, 2016. No actual tax benefit was realized from stock option exercises during these periods. As of March 31, 2017, 8,094,000 of the stock options issued by the Company are fully vested and 4,000,000 remain unvested. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 3 Months Ended |
Mar. 31, 2017 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | 8. RELATED PARTY TRANSACTIONS Through December 31, 2011, a founder of the company and significant shareholder, Dr. David Platt advanced $257,820 to the Company to fund start-up costs and operations. Advances by Dr. Platt carry an interest rate of 6.5% and were due on June 29, 2013. On May 7, 2012, Dr. Platt and the Company's former President and also a significant shareholder entered into promissory notes to advance to the Company an aggregate of $40,000. The notes accrue interest at 6.5% per year and were due June 30, 2013. The outstanding notes of $297,820 have been amended each year to extend the maturity dates. Most recently, effective June 30, 2015, the outstanding notes for Dr. Platt were amended to extend the maturity dates to June 30, 2017. The maturity date for the Company's former President remain June 30, 2016 and have been classified as a current liability within the accompanying balance sheet. On June 24, 2011, the Company entered into a definitive Licensing and Manufacturing Agreement (the "Agreement") with Advance Pharmaceutical Company Ltd. ("Advance Pharmaceutical"), a Hong Kong-based privately-held company. Under terms of the Agreement, the Company manufactures and supplies product in bulk for Advance Pharmaceutical. Advance Pharmaceutical is responsible for the packaging, marketing and distribution of SUGARDOWN® in certain territories within Asia. Advance Pharmaceutical, through a wholly owned subsidiary, has purchased an aggregate 1,799,800 shares of the Company’s common stock in conjunction with the Company’s private placement offerings during the years ended December 31, 2012 and 2011. The shares were purchased on the same terms as the other participants acquiring shares in the respective offerings. Conroy Chi-Heng Cheng is a director of Advance Pharmaceutical and joined the Company’s Board in December 2013. No revenue was generated pursuant to the Agreement for the three months ended March 31, 2017 or 2016. In December 2013, the Board of Directors agreed to indemnify Dr. Platt for legal costs incurred in connection with an arbitration (now concluded) initiated before the American Arbitration Association by Galectin Therapeutics, Inc. (formerly named Pro-Pharmaceuticals, Inc.) for which Dr. Platt previously served as CEO and Chairman. Galectin sought to rescind or reform the Separation Agreement entered into with Dr. Platt upon his resignation from Galectin to remove a $1.0 million milestone payment which Dr. Platt asserted he was entitled to receive and to be repaid all separation benefits paid to Dr. Platt. The Company initially capped the amount for which it would indemnify Dr. Platt at $150,000 in December 2013 and Dr. Platt agreed to reimburse the indemnification amounts paid by the Company should he prevail in the arbitration. The Board decided to indemnify Dr. Platt after considering a number of factors, including the scope of the Company’s existing indemnification obligations to officers and directors and the potential impact of the arbitration on the Company. In May 2014, the Board approved a $50,000 increase in indemnification support, solely for the payment of outside legal expenses. The Company recorded a total of $182,697 in costs associated with Dr. Platt’s indemnification, of which $119,401 was expensed in the year ended December 31, 2013 and of which $63,296 was expensed in the year ended December 31, 2014. In July 2014, the arbitration was concluded in favor of Dr. Platt, confirming the effectiveness of the separation agreement and payment was made to Dr. Platt in July 2014. On March 2, 2015, the Board of Directors voted to reduce the amount that Dr. Platt was required to reimburse the Company to $82,355 and to offset this amount against interest accrued in respect of the outstanding note payable to Dr. Platt. In addition, the Board determined that Dr. Platt would be charged interest related to the $182,697 indemnification payment since funds were received by Dr. Platt in July 2014. The Board of Directors concluded the foregoing constituted complete satisfaction of Dr. Platt’s indemnification by the Company. Accordingly, the Company has recorded the reduction in accrued interest through equity during the year ended December 31, 2015. As of March 31, 2017 and December 31, 2016, $24,598 and $24,131, respectively, of accrued interest in connection with the related party promissory notes, had been included in accrued expenses and other current liabilities on the accompanying balance sheet. In June 2015, the Company received $200,000 of cash proceeds from CJY Holdings Limited, in connection with a potential future exercise of its warrant. On November 12, 2015, the Company entered into a modification of a previously issued warrant agreement to CJY. The Board approved the reduction in the common stock warrant exercise prices from $0.50 to $1.00 per share to $0.17 per share. In connection with the June 2015 proceeds of $200,000 previously received by the Company and the reduction in the warrant exercise price, the Board approved the issuance of 1,194,440 shares of Common Stock to CJY in connection with the modified warrant agreement. These shares were issued on December 5, 2016. Prior to their issuance, $200,000 was recorded in common stock subscribed. During September 2015, the Company entered into a securities purchase agreement with CJY. Pursuant to this agreement, the Company issued to CJY a convertible promissory note in the principal amount of $750,000. The Note was amended during the fourth quarter to $1,200,000 and was amended again in 2016 to $1,752,000. This Note provided necessary bridge financing to the Company prior to a financing of $1,600,000 completed in the third quarter of 2016. Interest accrues at the rate of 10% per annum and is due upon maturity of the note in August 2018. The Company may prepay this Note and any accrued interest at any time. At any time on, amounts outstanding under the CJY Note are convertible into the Company’s common stock, in whole or in part, at the option of the lender, at a conversion price of $0.05 per share. A beneficial conversion feature of $1,642,000 was calculated and capped at the value of the note pursuant to ASC 470 - 20. The Company recorded amortization of the beneficial conversion feature as interest expense in the amount of $154,665 and $117,654 during the three months ended March 31, 2017 and 2016, respectively. Convertible notes payable – related party consist of the following at March 31, 2017 and December 31, 2016: 2017 2016 Principal balance $ 1,752,000 $ 1,752,000 Debt discount (842,874 ) (997,539 ) Outstanding, net of debt discount $ 909,126 $ 754,461 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Mar. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | 9. COMMITMENTS AND CONTINGENCIES Leases The Company currently leases office space in Lawrence, MA under a month to month lease. Prior to this location, the Company leased office space in Newton MA under a lease that expired July 31, 2016. The Company has no further obligation under that lease. The Company recognized rent expense of $900 and $4,950 during the three months ended March 31, 2017 and 2016, respectively. There are no future minimum lease payments under non-cancelable operating leases as of March 31, 2017. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 3 Months Ended |
Mar. 31, 2017 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | 10. SUBSEQUENT EVENTS The Company has evaluated events and transactions that occurred from March 31, 2017 through the date of filing, for possible disclosure and recognition in the financial statements. See discussed below material subsequent events that impact its financial statements or disclosures. On April 3, 2017, in accordance with the terms of a Securities Purchase Agreement, the Company issued 1,038,301 shares to an investor upon conversion of a note payable held by the investor for $75,000 including accrued interest of approximately $2,873. The cost basis for the shares issued was $0.075. On April 26, 2017, Boston Therapeutics, Inc. (the “Company”) entered into Securities Purchase Agreement with CJY Holdings Limited (“CJY") providing for the sale by the Company to CJY of 6% Subordinated Convertible Debenture in an amount of up to $1,000,000 (the "Debentures"). In addition to the Debentures, CJY will also receive stock purchase warrants (the "Warrants") to acquire 500,000 shares of common stock of the Company for every $50,000 in Debentures purchased. The Warrants are exercisable for five years at an exercise price of $0.10 and may be exercised on a cashless basis. The Company may only use the proceeds for the payment of services or materials associated with clinical trials. The Company closed on $200,000 in financing and issued the related Debentures and Warrants under this agreement on April 26, 2017. The Debentures bear interest at 6% per annum and mature two years from issuance. CJY may elect to convert all or part of the Debentures, plus accrued interest, at any time into shares of common stock of the Company at a conversion price of $0.10 per share. Interest on the Debentures is payable in cash or shares of common stock at $0.10 per share quarterly commencing June 30, 2017. The conversion price is subject to adjustment for stock dividends and stock splits. In addition, if after the original issue date of the Debentures, either (i) the volume weighted average price equals or exceeds $0.50 for 10 consecutive trading days or (ii) the Company's elects to lists a class of securities on a national securities exchange, the Company may cause CJY to convert all or part of the then outstanding principal amount of the Debentures plus, accrued but unpaid interest, liquidated damages and other amounts owed. CJY agreed to restrict its ability to convert the Debentures and exercise the Warrants and receive shares of common stock such that the number of shares of common stock held by CJY after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock. |
SUMMARY OF SIGNIFICANT ACCOUN16
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Mar. 31, 2017 | |
Accounting Policies [Abstract] | |
Company Overview | Company Overview Boston Therapeutics, Inc., headquartered in Lawrence, MA, (OTC: BTHE) is a leader in the field of complex carbohydrate chemistry. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: BTI-320, a non-systemic, non-toxic, therapeutic compound designed to reduce post-meal glucose elevation. In addition, a formulation of the material SUGARDOWN®, falls within the regulatory dietary supplement guidelines and is designed to reduce post-meal blood sugar increases. In its patent portfolio, the Company had laboratory practical development of a combination material called IPOXYN. In its initial phase, IPOXYN is a continuous intravenous drug for the prevention of necrosis and treatment of ischemia with a first target indication for assisting in the treatment of lower limb ischemia often associated with diabetes. The accompanying unaudited condensed financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and primarily a CRO/CMO contracted operating history. As shown in the accompanying unaudited condensed financial statements, the Company has an accumulated deficit of approximately $18.9 million and $390,000 cash on hand as of March 31, 2017. Management is restructuring and is currently seeking additional capital through private placements and public offerings of its common stock. In addition, the Company may seek to raise additional capital through public or private debt or equity financings as well as collaboration activities in order to fund our operations. Management anticipates that the current cash available will be sufficient to fund our planned operations into the second quarter of 2017. The future of the Company is dependent upon its ability to obtain continued financing and upon future profitable operations from the partnering, development and clarity of its new business opportunities. There can be no assurance that the Company will be successful in accomplishing its objectives. Without such additional capital, the Company may be required to cease operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue operations |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q. These condensed financial statements should be read in conjunction with the Company's financial statements for its year ended December 31, 2016 included in its Form 10-K filed with the SEC on March 28, 2017. In the opinion of management, the statements contain all adjustments, including normal recurring adjustments necessary in order to present fairly the financial position as of March 31, 2017 and the results of operations for the three month periods ended March 31, 2017 and 2016. The condensed balance sheet, as of December 31, 2016, was derived from the audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results disclosed in the statements of operations for the three month period ended March 31, 2017 are not necessarily indicative of the results to be expected for the full fiscal year. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
Accounts Receivable | Accounts Receivable Accounts receivable is stated at the amount management expects to collect from outstanding balances. Management establishes a reserve for doubtful accounts based on its assessment of the current status of individual accounts. Balances that remain outstanding after management has used reasonable collection efforts are written off against the allowance. There were no allowances for doubtful accounts as of March 31, 2017 and December 31, 2016. |
Inventory | Inventory Inventory consists of raw materials, and finished goods of SUGARDOWN®. Inventories are stated at the lower of cost (first-in, first-out) or market, not in excess of net realizable value. The Company adjusts the carrying value of its inventory for excess and obsolete inventory. The Company continues to monitor the valuation of its inventory. |
Revenue Recognition | Revenue Recognition The Company generates revenues from sales of SUGARDOWN®. Revenue is recognized when there is persuasive evidence that an arrangement exists, the price is fixed and determinable, the product is shipped in accordance with the customers’ Free On Board (FOB) shipping point terms and collectability is reasonably assured. In practice, the Company has not experienced or granted significant returns of product. Shipping fees charged to customers are included in revenue and shipping costs are included in costs of sales. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and notes payable. The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates fair value due to their short-term nature using level 3 inputs as defined above. The carrying value of the notes payable as of March 31, 2017 and December 31, 2016, evaluated using level 3 inputs defined above based on quoted market prices on rates available to the Company for debt with similar terms and maturities, approximates the fair value. |
Convertible Instruments | Convertible Instruments U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable ASC 480-10. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. |
Common Stock Purchase Warrants and Other Derivative Financial Instruments | Common Stock Purchase Warrants and Other Derivative Financial Instruments The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company’s free standing derivatives consisted of warrants to purchase common stock that were issued in connection with the issuance of debt and of embedded conversion options with senior convertible debentures. The Company evaluated these derivatives to assess their proper classification in the balance sheet as of March 31, 2017 using the applicable classification criteria enumerated under ASC 815-Derivatives and Hedging. The Company determined that certain embedded conversion and/or exercise features do not contain fixed settlement provisions. The convertible debentures contain a conversion feature such that the Company could not ensure it would have adequate authorized shares to meet all possible conversion demands. As such, the Company was required to record the debt and warrant derivatives which do not have fixed settlement provisions as liabilities and mark to market all such derivatives to fair value at the end of each reporting period. |
Stock-Based Compensation | Stock-Based Compensation Stock–based compensation, including grants of employee and non-employee stock options and modifications to existing stock options, is recognized in the income statement based on the estimated fair value of the awards . The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company has a limited history of market prices of the common stock, and as such volatility is estimated using historical volatilities over the prior three years. The expected life of the awards is estimated based on the simplified method. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of our awards. The dividend yield assumption is based on history and expectation of paying no dividends. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Stock-based compensation expense is recognized in the financial statements on a straight-line basis over the vesting period, based on awards that are ultimately expected to vest. The Company grants stock options to non-employee consultants from time to time in exchange for services performed for the Company. Equity instruments granted to non-employees are subject to periodic revaluation over their vesting terms. In general, the options vest over the contractual period of the respective consulting arrangement and, therefore, the Company revalues the options periodically and records additional compensation expense related to these options over the remaining vesting period. |
Loss per Share | Loss per Share Basic net loss per share is computed based on the net loss for the period divided by the weighted average actual shares outstanding during the period. Diluted net loss per share is computed based on the net loss for the period divided by the weighted average number of common shares and common equivalent shares outstanding during each period unless the effect of such common equivalent shares would be anti-dilutive. Common stock equivalents represent the dilutive effect of the assumed exercise of certain outstanding stock options using the treasury stock method. The weighted average number of common shares for the three month period ended March 31, 2017 did not include 60,227,273, and 12,094,000 and 28,404,669 for convertible notes payable and accrued interest, options and warrants, respectively, because of their anti-dilutive effect. The weighted average number of common shares for the three month period ended March 31, 2016 did not include 6,289,000 and 12,424,669 for options and warrants, respectively, because of their anti-dilutive effect. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows. |
INVENTORIES (Tables)
INVENTORIES (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Inventory Disclosure [Abstract] | |
Schedule of components of inventories | The components of inventories at March 31, 2017 and December 31, 2016, net of inventory reserves, were as follows: 2017 2016 Raw materials $ 34,919 $ 34,919 Finished goods 19,638 20,197 $ 54,557 $ 55,11 6 |
INTANGIBLE ASSETS (Tables)
INTANGIBLE ASSETS (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | Intangible assets consist of the following at March 31, 2017 and December 31, 2016: 2017 2016 SUGARDOWN® technology and patent applications $ 900,000 $ 900,000 Less accumulated amortization (412,500 ) (396,429 ) Intangible assets, net $ 487,500 $ 503,571 |
FAIR VALUE OF FINANCIAL MEASURE
FAIR VALUE OF FINANCIAL MEASUREMENTS (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of fair value on a recurring basis | Financial liabilities as of March 31, 2017 measured at fair value on a recurring basis are summarized below: March 31, Quoted Prices Significant Significant Derivative liability $ 1,193,980 $ - $ - $ 1,193,980 Warrant liability 1,103,811 - - 1,103,811 Total $ 2,297,791 $ - $ - $ 2,297,791 Financial liabilities as of December 31, 2016 measured at fair value on a recurring basis are summarized below: December 31, Quoted Prices Significant Significant Derivative liability $ 1,234,106 $ - $ - $ 1,234,106 Warrant liability 1,093,765 - - 1,093,765 Total $ 2,327,871 $ - $ - $ 2,327,87 1 |
Schedule of fair value of the conversion/exercise options | The fair value of the conversion/exercise options were calculated using a binomial lattice formula with the following weighted average assumptions during the three months ended March 31, 2017: Conversion option: At March 31, Inception 2017 Common Stock Closing Price $ 0.0945 $ 0.071 Conversion Price per Share $ 0.075 $ 0.075 Conversion Shares 21,333,334 21,333,334 Call Option Value 0.0839 0.056 Dividend Yield 0.00 % 0.00 % Volatility 212.53 % 214.34 % Risk-free Interest Rate 0.725 % 1.03 % Term 2.0 years 1.38 years Exercise option: At March 31, Inception 2017 Common Stock Closing Price $ 0.0945 $ 0.071 Conversion Price per Share $ 0.100 $ 0.100 Conversion Shares 16,000,000 16,000,000 Call Option Value 0.0929 0.069 Dividend Yield 0.00 % 0.00 % Volatility 212.53 % 214.34 % Risk-free Interest Rate 1.15 % 1.93 % Term 5.0 years 4.38 years |
Schedule of change in Company's Level 3 conversion note and warrant liability | The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis using significant unobservable input for the three months ended March 31, 2017: Debt Warrant Derivative Liability Balance, December 31, 2016 $ 1,234,106 $ 1,093,765 Aggregate amount of derivative instruments issued - - Change in fair value of derivative liabilities (40,126 ) 10,046 Balance, March 31, 2017 $ 1,193,980 $ 1,103,811 |
CONVERTIBLE NOTES PAYABLE (Tabl
CONVERTIBLE NOTES PAYABLE (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Debt Disclosure [Abstract] | |
Schedule of convertible notes payable | Convertible notes payable consist of the following at March 31, 2017 and December 31, 2016: 2017 2016 Principal balance $ 1,600,000 $ 1,600,000 Debt discount (833,923 ) (1,031,183 ) Deferred finance costs (172,782 ) (204,198 ) Outstanding, net of debt discount $ 593,295 $ 364,61 9 |
STOCKHOLDERS' EQUITY (Tables)
STOCKHOLDERS' EQUITY (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Equity [Abstract] | |
Schedule of common stock warrants activity | The following table summarizes the Company’s common stock warrant activity during the three months ended March 31, 2017: Warrants Weighted Average Outstanding as of December 31, 2016 28,424,669 $ 0.29 Granted - - Exercised - - Forfeited/cancelled (20,000 ) 1.15 Outstanding as of March 31, 2017 28,404,669 $ 0.2 9 |
STOCK OPTION PLAN AND STOCK-B22
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Schedule of activity under Stock Plans | The following table summarizes the Company’s stock option activity during the three months ended March 31, 2017: Shares Exercise Price per Weighted Average Outstanding as of December 31, 2016 12,289,000 $ 0.10-1.21 $ 0.39 Granted - - - Exercised - - - Options forfeited/cancelled (195,000 ) 0.10 0.10 Outstanding as of March 31, 2017 12,094,000 $ 0.10-1.21 $ 0.3 9 |
Schedule of information about stock options vested or expected to vest | The following table summarizes information about stock options that are vested or expected to vest at March 31, 2017: Vested or Expected to Vest Exercisable Options Weighted Weighted Weighted Weighted Average Average Average Average Exercise Remaining Aggregate Number Exercise Remaining Aggregate Exercise Number of Price Per Contractual Intrinsic of Price Contractual Intrinsic Price Options Share Life (Years) Value Options Per Share Life (Years) Value $ 0.10 1,600,000 $ 0.10 8.95 $ - 1,600,000 $ 0.10 8.95 $ - 0.18 934,000 0.18 6.25 - 934,000 0.18 6.25 - 0.20 2,150,000 0.20 4.66 - 2,150,000 0.20 4.66 - 0.37 58,000 0.37 5.42 - 58,000 0.37 5.42 - 0.40 2,000,000 0.40 4.42 - - 0.40 4.42 - 0.42 63,000 0.42 3.75 - 63,000 0.42 3.75 - 0.50 2,810,000 0.50 0.80 - 2,810,000 0.50 0.80 - 0.60 2,000,000 0.60 4.42 - - 0.60 4.42 - 0.69 100,000 0.69 7.00 - 100,000 0.69 7.00 - 1.21 379,000 1.21 6.78 - 379,000 1.21 6.78 - $ 0.10-1.21 12,094,000 $ 0.39 4.46 $ - 8,094,000 $ 0.39 4.46 $ - |
RELATED PARTY TRANSACTIONS (Tab
RELATED PARTY TRANSACTIONS (Tables) | 3 Months Ended |
Mar. 31, 2017 | |
Related Party Transactions [Abstract] | |
Schedule of non-vested stock options | Convertible notes payable – related party consist of the following at March 31, 2017 and December 31, 2016: 2017 2016 Principal balance $ 1,752,000 $ 1,752,000 Debt discount (842,874 ) (997,539 ) Outstanding, net of debt discount $ 909,126 $ 754,461 |
SUMMARY OF SIGNIFICANT ACCOUN24
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 3 Months Ended | ||
Mar. 31, 2017 | Mar. 31, 2016 | Dec. 31, 2016 | |
Accumulated deficit | $ (18,934,279) | $ (18,226,179) | |
Cash in hand | $ 390,000 | ||
Stock Options [Member] | |||
Anti dilutive weighted average number of common shares | 12,094,000 | 6,289,000 | |
Warrant [Member] | |||
Anti dilutive weighted average number of common shares | 28,404,669 | 12,424,669 | |
Share [Member] | |||
Anti dilutive weighted average number of common shares | 60,227,273 |
INVENTORIES (Details)
INVENTORIES (Details) - USD ($) | Mar. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2016 |
Inventory Disclosure [Abstract] | |||
Raw materials | $ 34,919 | $ 34,919 | |
Finished goods | 19,638 | 20,197 | |
Inventory, net | $ 54,557 | $ 55,116 | $ 55,116 |
INTANGIBLE ASSETS (Details)
INTANGIBLE ASSETS (Details) - USD ($) | Mar. 31, 2017 | Mar. 31, 2016 |
Intangible assets consist | ||
SUGARDOWN technology and patent applications | $ 900,000 | $ 900,000 |
Less accumulated amortization | (412,500) | (396,429) |
Intangible assets, net | $ 487,500 | $ 503,571 |
INTANGIBLE ASSETS (Details Narr
INTANGIBLE ASSETS (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Useful lives of intangible assets | 14 years | |
Amortization expense | $ 16,071 | $ 16,071 |
FAIR VALUE OF FINANCIAL INSTR28
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) | Mar. 31, 2017 | Dec. 31, 2016 |
Derivative liabilities | $ 1,193,980 | $ 1,234,106 |
Warrant liability | 1,103,811 | 1,093,765 |
Total | 2,297,791 | 2,327,871 |
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | ||
Derivative liabilities | ||
Warrant liability | ||
Total | ||
Significant Other Observable Inputs (Level 2) [Member] | ||
Derivative liabilities | ||
Warrant liability | ||
Total | ||
Significant Unobservable Inputs (Level 3) [Member] | ||
Derivative liabilities | 1,193,980 | 1,234,106 |
Warrant liability | 1,103,811 | 1,093,765 |
Total | $ 2,297,791 | $ 2,327,871 |
FAIR VALUE OF FINANCIAL INSTR29
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - $ / shares | Aug. 24, 2009 | Mar. 31, 2017 |
Conversion Option [Member] | ||
Common Stock Closing Price | $ 0.0945 | $ 0.071 |
Conversion Price per Share | $ 0.075 | $ 0.075 |
Conversion Shares | 21,333,334 | 21,333,334 |
Call Option Value | $ 0.0839 | $ 0.056 |
Dividend Yield | 0.00% | 0.00% |
Volatility | 212.53% | 214.34% |
Risk-free Interest Rate | 0.725% | 1.03% |
Term | 2 years | 1 year 4 months 17 days |
Exercise Option [Member] | ||
Common Stock Closing Price | $ 0.0945 | $ 0.071 |
Conversion Price per Share | $ 0.100 | $ 0.100 |
Conversion Shares | 16,000,000 | 16,000,000 |
Call Option Value | $ 0.0929 | $ 0.069 |
Dividend Yield | 0.00% | 0.00% |
Volatility | 212.53% | 214.34% |
Risk-free Interest Rate | 1.15% | 1.93% |
Term | 5 years | 4 years 4 months 17 days |
FAIR VALUE OF FINANCIAL INSTR30
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 2) | 3 Months Ended |
Mar. 31, 2017USD ($) | |
Debt Derivative [Member] | |
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] | |
Balance at beggining | $ 1,234,106 |
Aggregate amount of derivative instruments issued | |
Change in fair value of derivative liabilities | (40,126) |
Balance at ending | 1,193,980 |
Warrant Derivative [Member] | |
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] | |
Balance at beggining | 1,093,765 |
Aggregate amount of derivative instruments issued | |
Change in fair value of derivative liabilities | 10,046 |
Balance at ending | $ 1,103,811 |
CONVERTIBLE NOTES PAYABLE (Deta
CONVERTIBLE NOTES PAYABLE (Details) - USD ($) | Mar. 31, 2017 | Dec. 31, 2016 |
Outstanding, net of debt discount | $ 593,295 | $ 364,619 |
6% Convertible Debt [Member] | ||
Principal balance | 1,600,000 | 1,600,000 |
Debt discount | (833,923) | (1,031,183) |
Deferred finance costs | (172,782) | (204,198) |
Outstanding, net of debt discount | $ 593,295 | $ 364,619 |
CONVERTIBLE NOTES PAYABLE (De32
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($) | 3 Months Ended | |||
Mar. 31, 2017 | Sep. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2016 | |
Debt Instrument [Line Items] | ||||
Convertible debenture, conversion feature | $ 402,000 | |||
6% Convertible Debt [Member] | ||||
Debt Instrument [Line Items] | ||||
Face amount | 1,600,000 | $ 1,600,000 | ||
Proceeds from issuance of convertible notes payable | $ 1,327,300 | |||
Convertible debentures, interest rate | 6.00% | |||
Convertible debentures, maturity date | Sep. 15, 2018 | |||
Convertible debentures, conversion price | $ 0.075 | |||
Description of conversion feature | Certain anti-dilutive (reset) provisions and are subject to forced conversion if either i) the volume weighted average common stock price for each of any 10 consecutive trading days equals or exceeds $0.50, or (ii) the Company’s elects to lists a class of securities on a national securities exchange. | |||
Warrants issued | 16,000,000 | |||
Issue price (in dollars per share) | $ 0.10 | |||
Warrants, exercisable date | Sep. 15, 2021 | |||
Convertible debenture, conversion feature | $ 2,203,336 | |||
Debt issuance cost including discount on debt | 2,476,036 | |||
Debt discount | 272,700 | |||
Excess of interest charged | $ 876,036 | |||
Amortization of debt discount | $ 197,260 |
STOCKHOLDERS' EQUITY (Details)
STOCKHOLDERS' EQUITY (Details) | 3 Months Ended |
Mar. 31, 2017$ / sharesshares | |
Warrants | |
Outstanding at beginning | shares | 28,424,669 |
Granted | shares | |
Exercised | shares | |
Forfeited/cancelled | shares | (20,000) |
Outstanding at end | shares | 28,404,669 |
Weighted Average Exercise Price | |
Outstanding at beginning | $ / shares | $ 0.29 |
Granted | $ / shares | |
Exercised | $ / shares | |
Forfeited/cancelled | $ / shares | 1.15 |
Outstanding at end | $ / shares | $ 0.29 |
STOCKHOLDERS' EQUITY (Details N
STOCKHOLDERS' EQUITY (Details Narrative) - $ / shares | 12 Months Ended | |||
Dec. 31, 2013 | Mar. 31, 2017 | Dec. 31, 2016 | Nov. 02, 2015 | |
Preferred stock, authorized | 5,000,000 | 5,000,000 | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 | ||
Common stock, authorized | 400,000,000 | 400,000,000 | ||
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 | ||
Common stock, outstanding | 46,702,836 | 46,702,836 | ||
Warrant [Member] | ||||
Common stock, outstanding | 28,404,669 | |||
Minimum [Member] | ||||
Increased number of common stock | 100,000,000 | |||
Common stock, outstanding | 200,000,000 | |||
Maximum [Member] | ||||
Increased number of common stock | 200,000,000 | |||
Common stock, outstanding | 400,000,000 |
STOCK OPTION PLAN AND STOCK-B35
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details) | 3 Months Ended |
Mar. 31, 2017$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | |
Outstanding at beginning | shares | 12,289,000 |
Options forfeited/cancelled | shares | (195,000) |
Outstanding at end | shares | 12,094,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] | |
Outstanding at beginning | $ 0.39 |
Granted | |
Exercised | |
Options forfeited/cancelled | 0.10 |
Outstanding at end | 0.39 |
Minimum [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price per Share [Roll Forward] | |
Outstanding at beginning | 0.10 |
Granted | |
Exercised | |
Options forfeited/cancelled | |
Outstanding at end | 0.10 |
Maximum [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price per Share [Roll Forward] | |
Outstanding at beginning | 1.21 |
Granted | |
Exercised | |
Options forfeited/cancelled | 0.10 |
Outstanding at end | $ 1.21 |
STOCK OPTION PLAN AND STOCK-B36
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details 1) | 3 Months Ended |
Mar. 31, 2017USD ($)$ / sharesshares | |
Exercise Price 0.10 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 1,600,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.1 |
Weighted Average Remaining Contractual Life (Years) | 8 years 11 months 12 days |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 1,600,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.1 |
Weighted Average Remaining Contractual Life (Years) | 8 years 11 months 12 days |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.18 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 934,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.18 |
Weighted Average Remaining Contractual Life (Years) | 6 years 3 months |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 934,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.18 |
Weighted Average Remaining Contractual Life (Years) | 6 years 3 months |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.20 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 2,150,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.2 |
Weighted Average Remaining Contractual Life (Years) | 4 years 7 months 28 days |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 2,150,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.2 |
Weighted Average Remaining Contractual Life (Years) | 4 years 7 months 28 days |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.37 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 58,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.37 |
Weighted Average Remaining Contractual Life (Years) | 5 years 5 months 2 days |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 58,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.37 |
Weighted Average Remaining Contractual Life (Years) | 5 years 5 months 2 days |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.40 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 2,000,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.4 |
Weighted Average Remaining Contractual Life (Years) | 4 years 5 months 2 days |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.4 |
Weighted Average Remaining Contractual Life (Years) | 4 years 5 months 2 days |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.42 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 63,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.42 |
Weighted Average Remaining Contractual Life (Years) | 3 years 9 months |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 63,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.42 |
Weighted Average Remaining Contractual Life (Years) | 3 years 9 months |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.50 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 2,810,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.5 |
Weighted Average Remaining Contractual Life (Years) | 9 months 18 days |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 2,810,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.5 |
Weighted Average Remaining Contractual Life (Years) | 9 months 18 days |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.60 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 2,000,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.6 |
Weighted Average Remaining Contractual Life (Years) | 4 years 5 months 2 days |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.6 |
Weighted Average Remaining Contractual Life (Years) | 4 years 5 months 2 days |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.69 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 100,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.69 |
Weighted Average Remaining Contractual Life (Years) | 7 years |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 100,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.69 |
Weighted Average Remaining Contractual Life (Years) | 7 years |
Aggregate Intrinsic Value | $ | |
Exercise Price 1.21 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 379,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 1.21 |
Weighted Average Remaining Contractual Life (Years) | 6 years 9 months 11 days |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 379,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 1.21 |
Weighted Average Remaining Contractual Life (Years) | 6 years 9 months 11 days |
Aggregate Intrinsic Value | $ | |
Exercise Price 0.10 - 1.21 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] | |
Number of Options | shares | 12,094,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.39 |
Weighted Average Remaining Contractual Life (Years) | 4 years 5 months 16 days |
Aggregate Intrinsic Value | $ | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable Options [Abstract] | |
Number of Options | shares | 8,094,000 |
Weighted Average Exercise Price Per Share | $ / shares | $ 0.39 |
Weighted Average Remaining Contractual Life (Years) | 4 years 5 months 16 days |
Aggregate Intrinsic Value | $ |
STOCK OPTION PLAN AND STOCK-B37
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION (Details Narrative) - USD ($) | Sep. 07, 2013 | Dec. 31, 2012 | Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2016 | Dec. 31, 2011 | Dec. 31, 2010 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Options outstanding | 12,094,000 | 12,289,000 | |||||||
Weighted average fair value of stock options granted (in dollars per share) | $ 0.34 | $ 0.18 | |||||||
Stock-based compensation expense | $ 12,439 | $ 0 | |||||||
Weighted average remaining contractual life for options exercisable (in years) | 4 years 5 months 12 days | ||||||||
Aggregate intrinsic value exercisable | $ 0 | ||||||||
Aggregate intrinsic value exercised | 0 | 0 | |||||||
Tax benefit realized | $ 0 | $ 0 | |||||||
Number of share vested | 8,094,000 | ||||||||
Number of shares non vested | 4,000,000 | ||||||||
Non-Vested Stock Option [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Unrecognized compensation expense | $ 219,756 | ||||||||
Minimum [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Increased number of common stock | 100,000,000 | ||||||||
Vesting period | 1 year | ||||||||
Expiration period | 5 years | ||||||||
Maximum [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Increased number of common stock | 200,000,000 | ||||||||
Vesting period | 4 years | ||||||||
Expiration period | 10 years | ||||||||
2010 Stock Plan [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Increased number of common stock | 7,500,000 | ||||||||
Options outstanding | 250,000 | 250,000 | |||||||
Options available for grant | 7,250,000 | 5,000,000 | |||||||
2011 Stock Plan [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||
Increased number of common stock | 12,000,000 | 17,500,000 | |||||||
Options outstanding | 11,844,000 | 12,039,000 | |||||||
Options available for grant | 5,656,000 | 2,100,000 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - USD ($) | Mar. 31, 2017 | Dec. 31, 2016 |
Related Party Transaction [Line Items] | ||
Outstanding, net of debt discount | $ 909,126 | $ 754,461 |
CJY Holdings Limited [Member] | ||
Related Party Transaction [Line Items] | ||
Principal balance | 1,752,000 | 1,752,000 |
Debt discount | (842,874) | (997,539) |
Outstanding, net of debt discount | $ 909,126 | $ 754,461 |
RELATED PARTY TRANSACTIONS (D39
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | Dec. 05, 2016 | May 07, 2012 | Jun. 30, 2015 | May 31, 2014 | Mar. 31, 2017 | Mar. 31, 2016 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2016 | Nov. 12, 2015 | Sep. 30, 2015 | Mar. 02, 2015 |
Notes payable - related parties, current portion | $ 297,820 | $ 297,820 | ||||||||||||
Exercise price of warrants | $ 0.29 | $ 0.29 | ||||||||||||
Beneficial conversion feature | $ 402,000 | |||||||||||||
Dr. David Platt [Member] | ||||||||||||||
Advance from related party | $ 257,820 | |||||||||||||
Interest rate | 6.50% | |||||||||||||
Notes payable - related parties, current portion | 297,820 | |||||||||||||
Offsetting reimbursement amount against accrued interest | $ 82,355 | |||||||||||||
Accrued interest to related party | 24,598 | $ 35,542 | ||||||||||||
Dr. David Platt [Member] | Separation Agreement [Member] | ||||||||||||||
Milestone separation benefits | $ 1,000,000 | |||||||||||||
Reimbursement amount for indemnification | 150,000 | |||||||||||||
Payment of outside legal expenses | $ 50,000 | |||||||||||||
Expense associated with indemnification | $ 63,296 | $ 119,401 | ||||||||||||
Recognized cost of indemnification | $ 182,697 | |||||||||||||
Dr. David Platt [Member] | Promissory Notes [Member] | ||||||||||||||
Interest rate | 6.50% | |||||||||||||
Proceeds from promissory notes | $ 40,000 | |||||||||||||
Advance Pharmaceutical Company Ltd. [Member] | Licensing And Manufacturing Agreement [Member] | ||||||||||||||
Revenue generated from agreement | $ 0 | |||||||||||||
Advance Pharmaceutical Company Ltd. [Member] | Licensing And Manufacturing Agreement [Member] | Private Placement [Member] | ||||||||||||||
Number of shares issued | 1,799,800 | 1,799,800 | ||||||||||||
CJY Holdings Limited [Member] | ||||||||||||||
Number of shares issued | 1,194,440 | |||||||||||||
Proceeds from warrant exercises | $ 200,000 | |||||||||||||
Reduction in exercise price of warrants | 0.17 | |||||||||||||
CJY Holdings Limited [Member] | Minimum [Member] | ||||||||||||||
Exercise price of warrants | $ 0.50 | |||||||||||||
CJY Holdings Limited [Member] | Maximum [Member] | ||||||||||||||
Exercise price of warrants | $ 1 | |||||||||||||
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | ||||||||||||||
Interest rate | 10.00% | |||||||||||||
Face amount | 750,000 | |||||||||||||
Conversion price | $ 0.05 | |||||||||||||
Beneficial conversion feature | $ 1,642,000 | |||||||||||||
Amortization of the beneficial conversion feature | $ 154,665 | 117,654 | ||||||||||||
Bridge financing | $ 1,600,000 | |||||||||||||
Maturity date description | August 2,018 | |||||||||||||
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | Agreement 2015 [Member] | ||||||||||||||
Face amount | $ 1,200,000 | |||||||||||||
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | Agreement 2016 [Member] | ||||||||||||||
Face amount | $ 1,752,000 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2017 | Mar. 31, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Rent expense | $ 900 | $ 4,950 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | Apr. 26, 2017 | Apr. 03, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2016 | Nov. 12, 2015 |
Subsequent Event [Line Items] | ||||||
Exercise price (in dollars per share) | $ 0.29 | $ 0.29 | ||||
6% Convertible Debt [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Share price (in dollars per share) | $ 0.10 | |||||
Face amount | $ 1,600,000 | $ 1,600,000 | ||||
Warrants issued | 16,000,000 | |||||
Interest rate | 6.00% | |||||
Conversion price (in dollars per share) | $ 0.075 | |||||
CJY Holdings Limited [Member] | Maximum [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Exercise price (in dollars per share) | $ 1 | |||||
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Face amount | $ 750,000 | |||||
Conversion price (in dollars per share) | $ 0.05 | |||||
Subsequent Event [Member] | Investor [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Number of shares issued on debt conversion | 1,038,301 | |||||
Accrued interest on debt conversion | $ 75,000 | |||||
Share price (in dollars per share) | $ 0.075 | |||||
Subsequent Event [Member] | CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | 6% Convertible Debt [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Warrants issued | 500,000 | |||||
Warrant expiration period | 5 years | |||||
Proceeds from issuance of long term debt | $ 200,000 | |||||
Subsequent Event [Member] | CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | 6% Convertible Debt [Member] | Maximum [Member] | ||||||
Subsequent Event [Line Items] | ||||||
Face amount | $ 1,000,000 | |||||
Exercise price (in dollars per share) | $ 0.10 | |||||
Interest rate | 10.00% | |||||
Conversion price (in dollars per share) | $ 0.10 |